To assess the effectiveness of EMLA (eutectic mixture of local anaesthetics) cream on pain during venipuncture (VE) and intravenous (IV) insertion.
Data extraction
Two reviewers extracted the data and resolved any disagreements through discussion. Inter-rater agreement was measured. Data were extracted on: age; gender; health status of the participants; whether the participants were volunteers or patients; use of premedication before the intervention; study design; quality criteria; results; year and type of publication; country where the study was conducted; and the number and qualifications of the authors. Effect sizes were estimated for each study. Where effect sizes were not reported they were calculated from the data presented (the methods were described). Studies with more than one treatment arm were treated as separate interventions.
Methods of synthesis
How were the studies combined? The study characteristics were summarised in the text of the review. A pooled effect size with 95% confidence interval (CI) was estimated for VE and IV pain separately using a fixed-effect model. Pooled effect sizes were estimated using three different methods: unweighted, weighted by sample size, and weighted by quality score. The effect size was smallest when weighted by sample size; further meta-analyses were performed with weighting using sample size.
How were differences between studies investigated?
Statistical heterogeneity was assessed using the chi-squared statistic. The influence of the following moderator variables was investigated: study publication date; age of the participants; sample size; health status of the participants; site of VE or IV puncture; duration of EMLA application; method of pain measurement; research design; and study validity score. The fail-safe N was calculated. After finding significant statistical heterogeneity for IV insertion pain, an exploration of which studies were responsible for the heterogeneity was undertaken, two outlying studies were removed, and the metaanalysis was repeated. For IV pain, studies with different EMLA application times were compared: 60 minutes or less versus greater than 60 minutes. Potential sources of heterogeneity for studies with an EMLA application time of greater than 60 minutes were explored (using disjoint cluster analysis and other moderator variables).
Results of the review
Seven studies (9 treatment arms; 542 people) assessed VE pain: 5 RCTs and 3 repeated measures studies. Thirteen reports (612 people) assessed IV insertion pain: 10 RCTs and 3 repeated measures studies.
The overall quality scores ranged from 13 to 20 out of a possible 26. Inter-rater agreement for the data extraction ranged from 97 to 100%.
VE insertion pain.
The validity scores for the 7 studies ranged from 15 to 20. Five of the studies were funded. The sample size ranged from 18 to 140 people.
All of the studies found that EMLA cream significantly reduced VE pain. The fail-safe N was 374. The effect sizes ranged from 0.68 to 1.76; the pooled effect size was 1.05 (95% CI: 0.92, 1.34). No significant heterogeneity was detected for either significance levels (P=0.37) or effect sizes (P=0.69). The only moderator variable that influenced the results was sample size: as the sample size increased, the significance level of the results decreased (correlation, r = -0.37, P=0.01).
IV insertion pain.
The validity scores ranged from 13 to 20. Six of the studies were funded. The sample size ranged from 12 to 119 people.
Thirteen of the fourteen treatment arms found that EMLA cream significantly reduced IV pain. The fail-safe N was 994. Significant heterogeneity was detected for significance levels (P=0.0002) and for effect sizes (P<0.0001). After the removal of 2 studies with extreme effect sizes, the author reported that the remaining treatment arms were statistically homogeneous (P=0.03). The study quality score influenced the results (-0.52): as the quality increased, the effect size decreased. The effect sizes for these 10 remaining studies ranged from 0.62 to 2.13; the pooled effect size was 1.04 (95% CI: 0.84, 1.46). The moderator variables did not appear to influence the results.
